Skip Navigation


QJM Advance Access originally published online on February 8, 2006
QJM 2006 99(3):127-133; doi:10.1093/qjmed/hcl009
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/3/127    most recent
hcl009v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Smith, A.M.
Right arrow Articles by Channer, K.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, A.M.
Right arrow Articles by Channer, K.S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Review

The role of vasopressin in cardiorespiratory arrest and pulmonary hypertension

A.M. Smith1,2, C.M. Elliot3, D.G. Kiely3 and K.S. Channer2,4,

From the 1Hormone & Vascular Biology Group, Academic Unit of Endocrinology, Division of Genomic Medicine, The University of Sheffield, 2Department of Cardiology and 3Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust and 4Faculty of Health and Well-being, Sheffield Hallam University, Sheffield, UK

Address correspondence to: Professor K.S. Channer M131 Cardiology Royal Hallamshire Hospital Glossop Road, Sheffield S10 2JF. email: Kevin.Channer{at}sth.nhs.uk

Vasopressin is a peptide synthesized in the hypothalamus whose primary role is in fluid homeostasis. It has recently gained interest as a potential agent in the treatment of cardiorespiratory arrest. Initial human studies have shown benefits with vasopressin in patients with out of hospital ventricular fibrillation and asystolic cardiac arrest. One subgroup of patients not included in these trials is patients with pulmonary hypertension, who have a five-year mortality rate of 50%. Animal studies have shown vasopressin to be a vasodilator in the pulmonary vascular system of rats, under normoxic and hypoxic conditions, with conflicting results in canines. Human studies have shown conflicting results with increases, decreases and no changes seen in pulmonary artery pressures of patients with a variety of clinical conditions. Research needs to be done in patients with pulmonary hypertension regarding the potential role of vasopressin during cardiac arrest in this subgroup.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
C. Schummer, M. Wirsing, and W. Schummer
The Pivotal Role of Vasopressin in Refractory Anaphylactic Shock
Anesth. Analg., August 1, 2008; 107(2): 620 - 624.
[Abstract] [Full Text] [PDF]


Home page
Br J AnaesthHome page
L. C. Price, P. Forrest, V. Sodhi, D. L. Adamson, C. Nelson-Piercy, M. Lucey, and L. S. Howard
Use of vasopressin after Caesarean section in idiopathic pulmonary arterial hypertension
Br. J. Anaesth., October 1, 2007; 99(4): 552 - 555.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.